Hui Yang

Dr. Hui Yang


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
HYHui Yang
Hui Yang
QLQingqing Li
Qingqing Li
XCXingxing Chen
Xingxing Chen
MWMingzhe Weng
Mingzhe Weng
YHYakai Huang
Yakai Huang
MMMingzhe Ma
Mingzhe Ma
Therapeutic resistance represents a bottleneck to treatment in advanced gastric cancer (GC). Ferroptosis is an iron-dependent form of non-apoptotic cell death and is associated with anti-cancer therapeutic efficacy. Further investigations are required to clarify the underlying mechanisms. Ferroptosis-resistant GC cell lines are constructed. Dysregulated mRNAs between ferroptosis-resistant and parental cell lines are identified. The expression of SOX13/SCAF1 is manipulated in GC cell lines where relevant biological and molecular analyses are performed. Molecular docking and computational screening are performed to screen potential inhibitors of SOX13. We show that SOX13 boosts protein remodeling of electron transport chain (ETC) complexes by directly transactivating SCAF1. This leads to increased supercomplexes (SCs) assembly, mitochondrial respiration, mitochondrial energetics and chemo- and immune-resistance. Zanamivir, reverts the ferroptosis-resistant phenotype via directly targeting SOX13 and promoting TRIM25-mediated ubiquitination and degradation of SOX13. Here we show, SOX13/SCAF1 are important in ferroptosis-resistance, and targeting SOX13 with zanamivir has therapeutic potential.

9 January 2024 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
XWXingwei Wu
Xingwei Wu
MFMinjie Fu
Minjie Fu
CGChang Ge
Chang Ge
HZHanyu Zhou
Hanyu Zhou
HHHaoyu Huang
Haoyu Huang
HYHui Yang
Hui Yang

6 July 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
ZYZhen Yang
Zhen Yang
XLXiaocen Liu
Xiaocen Liu
HXHao Xu
Hao Xu
Andrew E. TeschendorffAndrew E. Teschendorff
Andrew E. Teschendorff
LXLingjie Xu
Lingjie Xu
HYHui Yang
Hui Yang
The expression dysregulation of microRNAs (miRNA) has been widely reported during cancer development, however, the underling mechanism remains largely unanswered. In the present work, we performed a systematic integrative study for genome-wide DNA methylation, copy number variation and miRNA expression data to identify mechanisms underlying miRNA dysregulation in lower grade glioma. We identify 719 miRNAs whose expression was associated with alterations of copy number variation or promoter methylation. Integrative multi-omics analysis revealed four subtypes with differing prognoses. These glioma subtypes exhibited distinct immune-related characteristics as well as clinical and genetic features. By construction of a miRNA regulatory network, we identified candidate miRNAs associated with immune evasion and response to immunotherapy. Finally, eight prognosis related miRNAs were validated to promote cell migration, invasion and proliferation through in vitro experiments. Our study reveals the crosstalk among DNA methylation, copy number variation and miRNA expression for immune regulation in glioma, and could have important implications for patient stratification and development of biomarkers for immunotherapy approaches.

16 February 2022 in Free Radical Biology and Medicine
Verified
Journal Article
Open access
MMMingzhe Ma
Mingzhe Ma
PKPengfei Kong
Pengfei Kong
YHYakai Huang
Yakai Huang
JWJiangli Wang
Jiangli Wang
XLXiaocen Liu
Xiaocen Liu
HYHui Yang
Hui Yang
Ferroptosis, a unique form of nonapoptotic-regulated cell death caused by overwhelming lipid peroxidation, represents an emerging tumor suppression mechanism. Growing evidence has demonstrated that cell metabolism plays an important role in the regulation of ferroptosis. Specifically, the association between methionine metabolism and ferroptosis remains undefined. We performed in vitro and in vivo experiments to evaluate the influence of methionine metabolism on ferroptosis sensitivity. Pharmacological and genetic blockade of the methionine cycle was utilized and relevant molecular analyses were performed. We identified MAT2A as a driver of ferroptosis resistance. Mechanistically, MAT2A mediates the production of S-adenosylmethionine (SAM), which upregulates ACSL3 by increasing the trimethylation of lysine-4 on histone H3 (H3K4me3) at the promoter area, resulting in ferroptosis resistance. Collectively, these results established a link between methionine cycle activity and ferroptosis vulnerability in gastric cancer.

1 April 2021 in Neuroscience Letters
Verified
Journal Article
Closed access
YXYang Xu
Yang Xu
XWXiaodong Wu
Xiaodong Wu
WHWenjie Hu
Wenjie Hu
DYDiJing Yu
DiJing Yu
ZSZhiding Shao
Zhiding Shao
LKLv Kun
Lv Kun

23 October 2020 in Oncology Reports
Verified
Journal Article
Open access
PDF file
YSYewen Shi
Yewen Shi
QZQingqing Zhang
Qingqing Zhang
MXMeng Xie
Meng Xie
YFYani Feng
Yani Feng
SMSijing Ma
Sijing Ma
HLHuanan Luo
Huanan Luo
Aberrant methylation is one of the most frequent epigenetic alterations that regulate the expression levels of genes, including long non‑coding RNAs (lncRNAs), in tumors. However, to the best of our knowledge, the expression and function of hepatic nuclear factor 1α antisense RNA 1 (HNF1A‑AS1) and its methylation condition have not yet been reported in the development and progression of laryngeal squamous cell carcinoma (LSCC). In the present study, the expression and methylation of HNF1A‑AS1 were first examined by reverse transcription‑quantitative PCR, bisulfite genomic sequencing and methylation‑specific polymerase chain reaction in samples from patients with LSCC, which were based on the in silico analysis using The Cancer Genome Atlas data, and were then further verified in LSCC cell lines with and without 5‑Aza‑2'‑deoxycytidine (5‑Aza‑dC) treatment. Subsequently, proliferation, cell cycle distribution, migration and invasion of LSCC cells following either knockdown or overexpression of HNF1A‑AS1 were determined in vitro. Furthermore, the characteristic of HNF1A‑AS1 on epithelial‑mesenchymal transition (EMT) changes was investigated in vitro and in vivo. The associations between the expression levels of HNF1A‑AS1 and tumorigenicity and cervical lymph node metastasis were assessed in a xenograft model in nude mice. In the present study, downregulation and hypermethylation in CpG sites of HNF1A‑AS1 were detected in LSCC tissues as well as metastatic cervical lymph nodes samples when compared with those in the adjacent non‑tumor tissues. Additionally, HNF1A‑AS1 inhibited proliferation, migration and invasion of LSCC cells in vitro by regulating the process of EMT. Furthermore, HNF1A‑AS1 inhibited tumor growth and metastasis by regulating EMT in vivo. Additionally, the migration and invasion abilities, and the expression levels of HNF1A‑AS1 and EMT markers in LSCC cells were significantly reversed by treatment with 5‑Aza‑dC. In summary, HNF1A‑AS1 was downregulated by hypermethylation in LSCC and laryngeal cancer cells. These findings suggested that HNF1A‑AS1 could serve as a tumor suppressor lncRNA in LSCC by regulating the EMT process, leading to the discovery of novel therapeutic targets and strategies for the treatment of patients with LSCC.